Risk evaluation of the use of complementary and alternative medicines in cancer

Renet, Sophie; Chevigny, Alix de; Hoacoglu, S.; Belkarfa, A.-L.; Jardin-Szucs, M.; Bézie, Yvonnick; Jouveshomme, Stéphane

doi:10.1016/j.pharma.2020.05.001

Cited by 9 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to acquired resistance or severe side effects, patients dissatisfied with conventional cancer treatment are increasingly turning to complementary alternative medicine (CAM) [8]. Around 50% of cancer patients worldwide presently use CAM during the course of their disease, whereby administration of natural herbs is the preferred CAM modality [9,10].…”

Section: Introductionmentioning

confidence: 99%

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro

Xie

Rutz

Maxeiner

et al. 2022

Cancers

View full text Add to dashboard Cite

Combined cisplatin–gemcitabine (GC) application is standard for treating muscle-invasive bladder cancer. However, since rapid resistance to treatment often develops, many patients turn to supplements in the form of plant-based compounds. Sulforaphane (SFN), derived from cruciferous vegetables, is one such compound, and the present study was designed to investigate its influence on growth and proliferation in a panel of drug-sensitive bladder cancer cell lines, as well as their gemcitabine- and cisplatin-resistant counterparts. Chemo-sensitive and -resistant RT4, RT112, T24, and TCCSUP cell lines were exposed to SFN in different concentrations, and tumor growth, proliferation, and clone formation were evaluated, in addition to apoptosis and cell cycle progression. Means of action were investigated by assaying cell-cycle-regulating proteins and the mechanistic target of rapamycin (mTOR)/AKT signaling cascade. SFN significantly inhibited growth, proliferation, and clone formation in all four tumor cell lines. Cells were arrested in the G2/M and/or S phase, and alteration of the CDK–cyclin axis was closely associated with cell growth inhibition. The AKT/mTOR signaling pathway was deactivated in three of the cell lines. Acetylation of histone H3 was up-regulated. SFN, therefore, does exert tumor-suppressive properties in cisplatin- and gemcitabine-resistant bladder cancer cells and could be beneficial in optimizing bladder cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro

Xie

Rutz

Maxeiner

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“… 3 Further, decisions about T&CM products use among people with serious conditions such as cancer maybe uninformed/misinformed. 4 Indeed, there are safety risks related to the quality of products, 5 potential adverse events including drug–herb/nutrient interactions, 6 and delays in initiating known effective treatments, all of which can easily be overlooked. 7 This is particularly the case for special population groups such as children, the elderly and people living with chronic or other complex health issues, among whom the risk of experiencing adverse drug reactions and drug–herb interactions may be increased.…”

Section: Introductionmentioning

confidence: 99%

“…However, many consumers consider T&CM products as ‘natural and therefore safe’, and thus may not extend the same caution towards their use as they would for prescription medicines 3. Further, decisions about T&CM products use among people with serious conditions such as cancer maybe uninformed/misinformed 4. Indeed, there are safety risks related to the quality of products,5 potential adverse events including drug–herb/nutrient interactions,6 and delays in initiating known effective treatments, all of which can easily be overlooked 7.…”

Section: Introductionmentioning

confidence: 99%

Towards consensus: defining and supporting a professional role for pharmacists associated with traditional and complementary medicines – a protocol of implementing an international e-survey

2022

View full text Add to dashboard Cite

IntroductionTraditional and complementary medicines (T&CM) are predominantly self-selected from retail outlets including pharmacies as part of self-care practices. Concerns about the appropriate and safe use of T&CM products raises questions about ‘should’ and ‘how’ pharmacists could adopt professional responsibilities. There lacks a consensus about the scope of these responsibilities, or the initiatives required to execute them. The aim of this study is to identify an international set of core responsibilities that support pharmacists’ contribution to ensuring the quality and safe use of T&CMs to promote public health.Methods and analysisAn international cross-sectional e-survey of pharmacists representing the six WHO regions will be conducted over a 12-month period. Pharmacists will be invited via representative organisations and professional networks within their respective country. Survey responses to statements about the relevance of T&CM to day-to-day practice; opinions about the bioethical and practice responsibilities; and support required to build their scope of practice associated with T&CM will be collected centrally via the online survey platform Survey Monkey and analysed using the Statistical Package for Social Sciences V.27 software for Windows. Bivariate statistical analysis will be conducted to examine the associations between agreement to statements within each section with key demographic variables, country of practice, pharmacy type, age, gender, qualification and years in practice. Cronbach’s alpha will be used to test the internal consistency of items from certain sections of the survey and evince their clarity to respondents of the questionnaire.Ethics and disseminationEthics approval has been obtained from the University of Macau (approval number SSHRE21-APP068-ICMS-01). The results of this survey will be used to inform key discussion points in a consensus process and a step towards developing an agreed and defined professional role for pharmacists in T&CMs.

show abstract

“…The equation is very simple and does not sit well with doctors in favor of an evidence-based medicine approach. People use herbal medicine; some herbal products can be beneficial for certain health disorders (e.g., [2][3][4][5][6][7][8]) and patients feel this as such [9]. Consumption of herbal medicines is widespread and increasing in recent years.…”

Section: Introductionmentioning

confidence: 99%

HDI Highlighter, The First Intelligent Tool to Screen the Literature on Herb–Drug Interactions

2022

View full text Add to dashboard Cite

Herbal food supplements are commonly used and can be an important part of patient self-care. Like all other bio-active and therapeutic products, they have a benefit/risk balance. These products are not without adverse effects and potentially interact with other therapies. Educating patients and providing information for health professionals about the risk of herb-drug interactions is key. One of the purposes of the biomedical literature is to inform prescribers. Scientific literature accessible on databases such as PubMed is dense and careful reading is time consuming. We propose a reading aid tool named "HDI highlighter" to help readers to find key information in clinical studies and case reports describing herb-drug interactions. It uses natural language processing algorithms (artificial intelligence) with a pharmaceutical focus. Semantic relation extraction for herb-drug interactions from the biomedical literature are overexpressed using keywords. We have tested it to review 120 published articles over the last 10 years. In these articles, we have shown that case reports often involved long-term or semi-long-term treatments such as cancer or human immunodeficiency virus therapies, antiepileptic drugs, or central nervous system drugs. Similarly, these classes of drugs are more extensively targeted by clinical studies. Herb-drug interactions described in case reports are identified in medicinal, recreational, and alimentary uses. They also usually lack a rigorous description of the herb(s) involved. Typically, clinical studies provide a complete description of protocols and dosages, with a few exceptions explained by patients' needs. Clinical studies on herbs are nevertheless conducted on a limited number of patients. All these limitations make the interpretation of herb-drug interactions complicated, but the HDI highlighter provides a quick overview of the herb-drug interaction literature.

show abstract

Risk evaluation of the use of complementary and alternative medicines in cancer

Cited by 9 publications

References 17 publications

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro

Towards consensus: defining and supporting a professional role for pharmacists associated with traditional and complementary medicines – a protocol of implementing an international e-survey

HDI Highlighter, The First Intelligent Tool to Screen the Literature on Herb–Drug Interactions

Contact Info

Product

Resources

About